Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPE-505 in SNHL with Speech-in-Noise Impairment
NCT04462198Phase 2Completed
- Sponsor
- Contineum Therapeutics
- Start
- Oct 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PIPE-505 in sensorineural hearing loss (SNHL), sponsored by Contineum Therapeutics. Started Oct 2020; status: completed.
02
Drugs
PIPE-505
03
Conditions
sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on NCT04462198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04462198.